DYADIC INTERNATIONAL INC: Annual Investor Guide

I’ve put together this guide to help you understand Dyadic International’s performance over the past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Think of Dyadic as the "engine room" for the biotech industry. They don't sell medicine at a pharmacy. Instead, they provide the tools—specifically their C1 and Dapibus™ platforms—that help other companies make vaccines, food ingredients, and lab chemicals faster and cheaper.

Their technology produces high-quality proteins at a lower cost than traditional methods. As of August 2025, they rebranded to Dyadic Applied BioSolutions. This reflects their shift toward becoming a commercial business that prioritizes near-term sales over long-term, speculative research.

2. Financial performance: The "Pivot"

Dyadic is in a growth phase. For 2024, they reported $2.1 million in revenue, down from $3.2 million the previous year due to the timing of research contracts.

Operating expenses remained high at $12.5 million, leading to a $10.4 million loss. They are actively working to stabilize their revenue by moving into food ingredients and lab supplies, which offer more predictable, recurring income. They recently launched products like AlbuFree™ DX to generate cash while they continue the expensive work of developing pharmaceutical technology.

3. Major wins and challenges

• Wins: The company is successfully branching out. Their Dapibus™ platform helps them enter markets with faster regulatory paths than medicine, generating revenue sooner. They also partnered with ERS Genomics to use CRISPR/Cas9 technology, which helps them develop new products more efficiently.
• Challenges: They rely heavily on a few customers, with a small group of partners accounting for over 50% of their revenue. Losing one contract would significantly impact their cash flow. Furthermore, they face the hurdle of navigating the costly, multi-year FDA approval process for their pharmaceutical applications.

4. Financial health

Dyadic is managing its cash carefully. They held about $8.5 million in cash as of their last report. With an annual spending rate of $8–$9 million, they have about 12 months of runway. They are not yet profitable and have a long history of losses. They do not pay dividends, choosing instead to keep cash for operations.

5. Key risks

• Stock Volatility: Because the company is small, the stock price can swing wildly on minor news.
• Dilution: To fund operations, Dyadic often sells more shares, which reduces your ownership percentage and the potential value of your shares.
• Intellectual Property: The business relies on their C1 platform patents. If they fail to defend these patents or lose access to licensed technology, they lose their competitive edge.
• Listing Risks: They must keep their share price above $1.00 to stay on the Nasdaq. If the price stays low for too long, they risk being delisted, which makes it harder to buy or sell the stock.

6. Future outlook

Dyadic is betting that their sustainable protein platforms will become the industry standard. Their goal is to move from a service-based model to a product-licensing model. Success depends on turning their current collaborations into reliable, long-term revenue streams, which would reduce their need to sell more shares to stay afloat.

Investor Takeaway: Dyadic is a high-risk, high-reward play. They have a clear technology advantage, but they are currently burning cash to reach profitability. If you are considering an investment, watch their ability to secure recurring revenue from their new product lines—this is the key to proving they can survive without constantly raising more money from shareholders.